Skip to main content
Top
Published in: BMC Medicine 1/2019

Open Access 01-12-2019 | Care | Research article

Implementation of genotype-guided dosing of warfarin with point-of-care genetic testing in three UK clinics: a matched cohort study

Authors: Andrea L. Jorgensen, Clare Prince, Gail Fitzgerald, Anita Hanson, Jennifer Downing, Julia Reynolds, J. Eunice Zhang, Ana Alfirevic, Munir Pirmohamed

Published in: BMC Medicine | Issue 1/2019

Login to get access

Abstract

Background

Warfarin is a widely used oral anticoagulant. Determining the correct dose required to maintain the international normalised ratio (INR) within a therapeutic range can be challenging. In a previous trial, we showed that a dosing algorithm incorporating point-of-care genotyping information (‘POCT-GGD’ approach) led to improved anticoagulation control. To determine whether this approach could translate into clinical practice, we undertook an implementation project using a matched cohort design.

Methods

At three clinics (implementation group; n = 119), initial doses were calculated using the POCT-GGD approach; at another three matched clinics (control group; n = 93), patients were dosed according to the clinic’s routine practice. We also utilised data on 640 patients obtained from routinely collected data at comparable clinics. Primary outcome was percentage time in target INR range. Patients and staff from the implementation group also provided questionnaire feedback on POCT-GGD.

Results

Mean percentage time in INR target range was 55.25% in the control group and 62.74% in the implementation group; therefore, 7.49% (95% CI 3.41–11.57%) higher in the implementation group (p = 0.0004). Overall, patients and staff viewed POCT-GGD positively, suggesting minor adjustments to allow smooth implementation into practice.

Conclusions

In the first demonstration of the implementation of genotype-guided dosing, we show that warfarin dosing determined using an algorithm incorporating genetic and clinical factors can be implemented smoothly into clinic, to ensure target INR range is reached sooner and maintained. The findings are like our previous randomised controlled trial, providing an alternative method for improving the risk-benefit of warfarin use in daily practice.
Appendix
Available only for authorised users
Literature
1.
go back to reference Burns M. Management of narrow therapeutic index drugs. J Thromb Thrombolysis. 1999;7(2):137–43.CrossRef Burns M. Management of narrow therapeutic index drugs. J Thromb Thrombolysis. 1999;7(2):137–43.CrossRef
2.
go back to reference Gong IY, Schwarz UI, Crown N, Dresser GK, et al. Clinical and genetic determinants of warfarin pharmacokinetics and pharmacodynamics during treatment initiation. PLoS One. 2011;6(11):e27808.CrossRef Gong IY, Schwarz UI, Crown N, Dresser GK, et al. Clinical and genetic determinants of warfarin pharmacokinetics and pharmacodynamics during treatment initiation. PLoS One. 2011;6(11):e27808.CrossRef
3.
go back to reference Johnson JA, Gong L, Whirl-Carrillo M, Gage BF, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin Pharmacol Ther. 2011;90(4):625–9.CrossRef Johnson JA, Gong L, Whirl-Carrillo M, Gage BF, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin Pharmacol Ther. 2011;90(4):625–9.CrossRef
4.
go back to reference Wadelius M, Pirmohamed M. Pharmacogenetics of warfarin: current status and future challenges. Pharmacogenomics J. 2007;7(2):99–111.CrossRef Wadelius M, Pirmohamed M. Pharmacogenetics of warfarin: current status and future challenges. Pharmacogenomics J. 2007;7(2):99–111.CrossRef
5.
go back to reference Bourgeois S, Jorgensen A, Zhang EJ, Hanson A, et al. A multi-factorial analysis of response to warfarin in a UK prospective cohort. Genome Med. 2016;8(1):2.CrossRef Bourgeois S, Jorgensen A, Zhang EJ, Hanson A, et al. A multi-factorial analysis of response to warfarin in a UK prospective cohort. Genome Med. 2016;8(1):2.CrossRef
6.
go back to reference Jorgensen AL, FitzGerald RJ, Oyee J, Pirmohamed M, et al. Influence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysis. PLoS One. 2012;7(8):e44064.CrossRef Jorgensen AL, FitzGerald RJ, Oyee J, Pirmohamed M, et al. Influence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysis. PLoS One. 2012;7(8):e44064.CrossRef
7.
go back to reference Yang J, Chen Y, Li X, Wei X, et al. Influence of CYP2C9 and VKORC1 genotypes on the risk of hemorrhagic complications in warfarin-treated patients: a systematic review and meta-analysis. Int J Cardiol. 2013;168(4):4234–43.CrossRef Yang J, Chen Y, Li X, Wei X, et al. Influence of CYP2C9 and VKORC1 genotypes on the risk of hemorrhagic complications in warfarin-treated patients: a systematic review and meta-analysis. Int J Cardiol. 2013;168(4):4234–43.CrossRef
8.
go back to reference Francis B, Lane S, Pirmohamed M, Jorgensen A. A review of a priori regression models for warfarin maintenance dose prediction. PLoS One. 2014;9(12):e114896.CrossRef Francis B, Lane S, Pirmohamed M, Jorgensen A. A review of a priori regression models for warfarin maintenance dose prediction. PLoS One. 2014;9(12):e114896.CrossRef
9.
go back to reference Consortium TIWP. Estimation of the Warfarin dose with clinical and Pharmacogenetic data. N Engl J Med. 2009;360(8):753–64.CrossRef Consortium TIWP. Estimation of the Warfarin dose with clinical and Pharmacogenetic data. N Engl J Med. 2009;360(8):753–64.CrossRef
10.
go back to reference Pirmohamed M, Burnside G, Eriksson N, Jorgensen AL, et al. A randomized trial of genotype-guided dosing of warfarin. N Engl J Med. 2013;369(24):2294–303.CrossRef Pirmohamed M, Burnside G, Eriksson N, Jorgensen AL, et al. A randomized trial of genotype-guided dosing of warfarin. N Engl J Med. 2013;369(24):2294–303.CrossRef
11.
go back to reference Pinnock H, Barwick M, Carpenter CR, Eldridge S, et al. Standards for Reporting Implementation Studies (StaRI) statement. BMJ. 2017;356:i6795.CrossRef Pinnock H, Barwick M, Carpenter CR, Eldridge S, et al. Standards for Reporting Implementation Studies (StaRI) statement. BMJ. 2017;356:i6795.CrossRef
13.
go back to reference R Development Core Team. R: A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2010. R Development Core Team. R: A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2010.
14.
go back to reference Rosendaal FR, Cannegieter SC, van der Meer FJ, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993;69(3):236–9.CrossRef Rosendaal FR, Cannegieter SC, van der Meer FJ, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993;69(3):236–9.CrossRef
15.
go back to reference Lee MTM, Klein TE. Pharmacogenetics of Warfarin: challenges and opportunities. J Hum Genet. 2013;58(6):334–8.CrossRef Lee MTM, Klein TE. Pharmacogenetics of Warfarin: challenges and opportunities. J Hum Genet. 2013;58(6):334–8.CrossRef
16.
go back to reference Rothwell PM. External validity of randomised controlled trials: “to whom do the results of this trial apply?”. Lancet. 2005;365(9453):82–93.CrossRef Rothwell PM. External validity of randomised controlled trials: “to whom do the results of this trial apply?”. Lancet. 2005;365(9453):82–93.CrossRef
17.
go back to reference Van Spall HG, Wallentin L, Yusuf S, Eikelboom JW, et al. Variation in warfarin dose adjustment practice is responsible for differences in the quality of anticoagulation control between centers and countries: an analysis of patients receiving warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial. Circulation. 2012;126(19):2309–16.CrossRef Van Spall HG, Wallentin L, Yusuf S, Eikelboom JW, et al. Variation in warfarin dose adjustment practice is responsible for differences in the quality of anticoagulation control between centers and countries: an analysis of patients receiving warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial. Circulation. 2012;126(19):2309–16.CrossRef
18.
go back to reference Mega JL, Walker JR, Ruff CT, Vandell AG, et al. Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet. 2015;385(9984):2280–7.CrossRef Mega JL, Walker JR, Ruff CT, Vandell AG, et al. Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet. 2015;385(9984):2280–7.CrossRef
19.
go back to reference Vandell AG, Walker J, Brown KS, Zhang G, et al. Genetics and clinical response to warfarin and edoxaban in patients with venous thromboembolism. Heart. 2017;103(22):1800–5.CrossRef Vandell AG, Walker J, Brown KS, Zhang G, et al. Genetics and clinical response to warfarin and edoxaban in patients with venous thromboembolism. Heart. 2017;103(22):1800–5.CrossRef
20.
go back to reference Johnson JA, Caudle KE, Gong L, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for pharmacogenetics-guided warfarin dosing: 2017 update. Clin Pharmacol Ther. 2017;102(3):397–404.CrossRef Johnson JA, Caudle KE, Gong L, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for pharmacogenetics-guided warfarin dosing: 2017 update. Clin Pharmacol Ther. 2017;102(3):397–404.CrossRef
21.
go back to reference Verhoef TI, Redekop WK, Langenskiold S, Kamali F, et al. Cost-effectiveness of pharmacogenetic-guided dosing of warfarin in the United Kingdom and Sweden. Pharmacogenomics J. 2016;16(5):478–84.CrossRef Verhoef TI, Redekop WK, Langenskiold S, Kamali F, et al. Cost-effectiveness of pharmacogenetic-guided dosing of warfarin in the United Kingdom and Sweden. Pharmacogenomics J. 2016;16(5):478–84.CrossRef
22.
go back to reference Kimmel SE, French B, Kasner SE, Johnson JA, et al. A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med. 2013;369(24):2283–93.CrossRef Kimmel SE, French B, Kasner SE, Johnson JA, et al. A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med. 2013;369(24):2283–93.CrossRef
23.
go back to reference Pirmohamed M, Kamali F, Daly AK, Wadelius M. Oral anticoagulation: a critique of recent advances and controversies. Trends Pharmacol Sci. 2015;36(3):153–63.CrossRef Pirmohamed M, Kamali F, Daly AK, Wadelius M. Oral anticoagulation: a critique of recent advances and controversies. Trends Pharmacol Sci. 2015;36(3):153–63.CrossRef
24.
go back to reference Gage BFBA, Lin H, Woller SC, Stevens SM, Al-Hammadi N, Li J, Rodríguez T Jr, Miller JP, McMillin GA, Pendleton RC, Jaffer AK, King CR, Whipple BD, Porche-Sorbet R, Napoli L, Merritt K, Thompson AM, Hyun G, Anderson JL, Hollomon W, Barrack RL, Nunley RM, Moskowitz G, Dávila-Román V, Eby CS. Effect of genotype-guided warfarin dosing on clinical events and anticoagulation control among patients undergoing hip or knee arthroplasty: the GIFT randomized clinical trial. JAMA. 2017;318(12):1115–24.CrossRef Gage BFBA, Lin H, Woller SC, Stevens SM, Al-Hammadi N, Li J, Rodríguez T Jr, Miller JP, McMillin GA, Pendleton RC, Jaffer AK, King CR, Whipple BD, Porche-Sorbet R, Napoli L, Merritt K, Thompson AM, Hyun G, Anderson JL, Hollomon W, Barrack RL, Nunley RM, Moskowitz G, Dávila-Román V, Eby CS. Effect of genotype-guided warfarin dosing on clinical events and anticoagulation control among patients undergoing hip or knee arthroplasty: the GIFT randomized clinical trial. JAMA. 2017;318(12):1115–24.CrossRef
25.
go back to reference Syn NL, Wong AL, Lee SC, Teoh HL, et al. Genotype-guided versus traditional clinical dosing of warfarin in patients of Asian ancestry: a randomized controlled trial. BMC Med. 2018;16(1):104.CrossRef Syn NL, Wong AL, Lee SC, Teoh HL, et al. Genotype-guided versus traditional clinical dosing of warfarin in patients of Asian ancestry: a randomized controlled trial. BMC Med. 2018;16(1):104.CrossRef
26.
go back to reference Pirmohamed M. Warfarin: the end or the end of one size fits all. J Personalized Med. 2018;8(3):22.CrossRef Pirmohamed M. Warfarin: the end or the end of one size fits all. J Personalized Med. 2018;8(3):22.CrossRef
27.
go back to reference Gulilat M, Tang A, Gryn SE, Leong-Sit P, et al. Interpatient variation in rivaroxaban and apixaban plasma concentrations in routine care. Can J Cardiol. 2017;33(8):1036–43.CrossRef Gulilat M, Tang A, Gryn SE, Leong-Sit P, et al. Interpatient variation in rivaroxaban and apixaban plasma concentrations in routine care. Can J Cardiol. 2017;33(8):1036–43.CrossRef
28.
go back to reference Burn J, Pirmohamed M. Direct oral anticoagulants versus warfarin: is new always better than the old? (vol 5, year 2018). Open Heart. 2018;5(1):e000712.CrossRef Burn J, Pirmohamed M. Direct oral anticoagulants versus warfarin: is new always better than the old? (vol 5, year 2018). Open Heart. 2018;5(1):e000712.CrossRef
Metadata
Title
Implementation of genotype-guided dosing of warfarin with point-of-care genetic testing in three UK clinics: a matched cohort study
Authors
Andrea L. Jorgensen
Clare Prince
Gail Fitzgerald
Anita Hanson
Jennifer Downing
Julia Reynolds
J. Eunice Zhang
Ana Alfirevic
Munir Pirmohamed
Publication date
01-12-2019
Publisher
BioMed Central
Keywords
Care
Warfarin
Published in
BMC Medicine / Issue 1/2019
Electronic ISSN: 1741-7015
DOI
https://doi.org/10.1186/s12916-019-1308-7

Other articles of this Issue 1/2019

BMC Medicine 1/2019 Go to the issue